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Radical-mediated thiol-ene strategy for photoactivation of thiol-
containing drugs in cancer cells 
Shuang Sun,[a] Bruno L. Oliveira,[a] Gonzalo Jiménez-Osés,[b] and Gonçalo J. L. Bernardes*[a,c] 
Abstract: Photo-activated drugs provide an opportunity to improve 
efficacy alongside reducing side-effects in the treatment of severe 
diseases, such as cancer. Herein, we describe a photoactivation 
decaging method of isobutylene-caged thiols through a UV-initiated 
thiol-ene reaction. The method was demonstrated with an 
isobutylene-caged cysteine, cyclic disulfide-peptide and thiol-
containing drug, all of which were rapidly and efficiently released 
under mild UV irradiation in the presence of thiol sources and a 
photoinitiator. Importantly, we show that the activity of histone 
deacetylase inhibitor Largazole can be switched-off when stapled, but 
selectively switched-on when irradiated with non-phototoxic light in 
cancer cells. 
In recent decades, precision medicine has drawn a lot of attention 
for the effective treatment of various diseases, especially cancer. 
Currently, as a result of a lack of selectivity in the pathological 
sites, the development of new, effective and safe therapies 
remains challenging. Among various new methods, the recently 
developed light-mediated treatment is recognized as a promising 
approach to achieve controlled activation of medicine at 
pathological sites[1], which could significantly reduce the side 
effects of chemotherapy. So far, in the battle against cancer, 
several types of light-activated anti-cancer reagents, which can 
be switched on conditionally with irradiation, have been 
investigated[2]. The structures of these photocaged drugs include 
various ultraviolet, near infra-red or visible responsive moieties[3], 
such as o-nitrobenzyl[2a, 4], coumarinyl ester[5], metal complexes[2e, 
6]. These photo-responsive structures offer an extensive toolbox 
for use in cancer therapies and other biological applications. 
However, issues and challenges remain in this field, such as using 
non-toxic wavelength, achieving rapid and efficient conversion 
and improving the bioavailability of the prodrug. Therefore, there 
is still demand for new designs and new developments for photo-
mediated therapy. 
Thiol-ene reactions (Scheme 1), a conjugation between a thiol 
and an alkene, have been known since the early 1900s[7]. The 
coupling reaction proceeds through two mechanisms, photo-
initiated free-radical addition and catalyzed Michael addition 
reactions. There are several desirable features of a click reaction, 
rapid reaction rates, ease of implementation, high yields and rates 
of conversion[8], so thiol-ene ‘click’ reactions have been 
increasingly used for various applications, such as 
biofunctionalization[9], surface and polymer modification, 
polymerization[10], and so on[8, 11]. Recently, isobutylene-bridged 
polymer networks have been extensively studied to synthesize 
polymer networks through radical-initiated thiol-ene chemistry[12]. 
This covalently cross-linked network is able to undergo photo-
mediated, reversible cleavage of its isobutylene backbone to 
allow chain rearrangement and relieve of structural strain. This 
method has also been used to provide a reactive handle for 
reversible addition and exchange of biochemical moieties under 
cytocompatible conditions[12d]. Key to this reaction is the 
isobutylene structure capable of addition-fragmentation chain 
transfer (AFCT), in which the structure is attacked by the photo-
initiated thiol radical in the presence of a photoinitiator (PI) to 
release the caged thiol part. 
 
Scheme 1. a. General thiol-ene coupling reaction; b. the thiol-isobutylene 
decaging reaction. 
Inspired by this AFCT reaction, we hypothesized that the 
isobutylene structure could be used as a bridging graft to cage 
thiol-drugs and allow further controlled activation of anti-cancer 
drugs by means of a radical-mediated thiol-ene mechanism 
(Scheme 1). Previously, we reported a one-pot macrocyclization 
strategy [with tris(2-carboxyethyl)phosphine (TCEP)] for thiol-
containing peptides by using an isobutylene graft, which can 
significantly enhance both membrane permeability and binding 
activity of the corresponding macrocycles[13]. The isobutylene 
graft can be rapidly and efficiently installed onto reduced thiol 
groups in a biocompatible manner because of the high reactivity 
of the bis-bromo isobutylene. Our research began with N-tert-
butyloxycarbonyl(Boc)-L-cysteine 1, which was protected with bis-
bromo isobutylene (Table 1 and Supporting Information). Stapled 
cysteine 2 was then screened under a series of conditions. Firstly, 
different PIs were tested with the same amounts of thiol source, 
1-thio-β-D-glucose tetraacetate, and stapled cysteine under 
irradiation at 365 nm. The reaction with water-soluble PI 2,2’-
azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride (Vazo 44) 
did not progress after 2 hours. However, the other PI, 2,2-
dimethoxy-2-phenylacetophenone (DPAP) successfully 
promoted the reaction and released N-Boc-cysteine 1. β-
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Mercaptoethanol (BME) was also tested as the thiol compound 
under the same conditions. This reaction released the cysteine in 
a slightly lower yield, which suggests that different thiol sources 
could be used to promote the reaction. However, when N,N-
dimethylformamide (DMF) was used as solvent, two disulfides 
between the thiol-glucose and N-Boc-cysteine 1, and N-Boc-
cystine were observed. To evaluate the reaction and calculate the 
isolated yield, TCEP was added to reduce the disulfides after the 
reaction. Under these conditions, the reaction was complete 
within 15 mins and gave a relatively high yield (65%). Moreover, 
the reaction was also rapid and efficient when glutathione was 
used as a thiol source in a mixed solvent of DMF and water, which 
shows that the reaction is practical for an aqueous environment. 
Then, the feasibility of our strategy was investigated with an 
isobutylene cyclized 5-mer peptide that bears two terminal 
cysteines and synthesized by solid-phase peptide synthesis[13]. 
The short peptide was completely converted into the disulfide 
derivative within 15 mins under the same conditions described 
previously (Figure 1). 
 
Table 1. Optimization of the thiol-ene decaging reaction. 
 
Entry PI Thiol Solvent TCEP 
Time 
(min) 
Yield 
(%) 
1 Vazo44 4AcGlcSH MeOH - 120 0 
2 DPAP 4AcGlcSH CH2Cl2 - 120 54 
3 DPAP BME CH2Cl2 - 120 37 
4 DPAP 4AcGlcSH DMF - 120 [a] 
5 DPAP 4AcGlcSH DMF - 15 [a] 
6 DPAP 4AcGlcSH DMF + 15 65 
7 DPAP GSH 
DMF/H2O 
1/1 
+ 15 67 
[a]A mixture of disulfides between cysteine and thiol-glucose and cystine. PI, 
Photoinitiator; 4AcGlcSH, 1-thio-β-D-glucose tetraacetate; BME, β-
mercaptoethanol; GSH, glutathione. 
To demonstrate that the release of the thiol compound is by 
means of a radical-mediated thiol-ene mechanism, a series of 
control experiments were conducted (Table 2 and Supporting 
Information). As shown in the table, a thiol source, UV irradiation 
and a PI are essential for the decaging reaction. When radical 
scavenger (2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO) was 
added to the reaction, it terminated the reaction by forming an 
intermediate with the DPAP fragmentation, which suggests that 
the reaction is mediated by radicals. 
 
 
Figure 1. Thiol-ene decaging reaction of isobutylene-cyclized peptide. a. The 
decaging reaction of stapled CAAAC peptide with 1-thio-β-D-glucose 
tetraacetate. b. HPLC traces of the starting material and reaction mixture. Blue, 
stapled CAAAC peptide; Red, reaction mixture after 15 min. 
The proposed mechanism for the radical-mediated thiol-ene 
decaging reaction was studied by Quantum Mechanical 
calculations using abbreviated thiol models (see Supporting 
Information) and is shown as Scheme 2. After generation of the 
thiol radical by the PI under UV irradiation, the isobutylene grafted 
structure undergoes a fast thiol-ene anti-Markovnikov addition 
with a calculated activation energy of ΔG‡  14 kcal mol–1 at the 
PCM(H2O)/M06-2X/6-31++G(2,p) theory level, to generate a 
symmetric tertiary carbon-centered radical intermediate. Then, 
the unstable radical intermediate undergoes a β-scission at a very 
similar reaction rate regenerating the isobutylene linkage and 
resulting in a mixed caged compound, which can be again 
attacked by another thiol radical following the same mechanism 
to release the other unit of the caged thiol compound. The process 
is nearly thermoneutral and reversible until two decaged radical 
thiols collapse forming a stable disulfide bond (Scheme 2). 
 
Table 2. Control studies of thiol-ene decaging reactions between 
isobutylene-grafted cysteine and thiol-glucose. 
Entry Thiol 
Stapled 
Cys 2 
UV DPAP TEMPO 
Conversion 
(%) 
1 + + + + - 100 
2 + + - + - no reaction 
3 + - + + - no reaction 
4 - + + + - no reaction 
5[a] + + + + + no reaction 
[a]A mixture of disulfides between cysteine and thiol-glucose and cystine. PI, 
Photoinitiator; 4AcGlcSH, 1-thio-β-D-glucose tetraacetate; BME, β-
mercaptoethanol; GSH, glutathione. 
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Scheme 2. Proposed mechanism of the radical-mediated thiol-isobutylene 
decaging reaction. 
With all this knowledge in hand and to demonstrate that this 
strategy is practical to activate drugs in vitro, we applied our 
method to potent histone deacetylase inhibitor (HDAC) Largazole. 
Cyclic depsipeptide Largazole is a marine natural product, and its 
derivatives are recognized as promising potential anticancer 
therapeutics. Cyclic depsipeptide Largazole is a marine natural 
product, and its derivatives are recognized as promising potential 
anticancer therapeutics. Largazole possesses remarkable and 
preferential growth-inhibitory activity against cancer cell lines 
relative to corresponding non-transformed cells[14]. The octanoyl 
tail in Largazole has better cell-permeability than the active free 
thiol species, Largazole thiol, the latter of which is formed inside 
cells by esterase or lipase-based cleavage of the octanoyl 
residue[15]. The free thiol group binds to the active site Zn2+-
domain within the HDAC enzyme, which results in a potent 
inhibitory effect. Thus, the thiol-ene decaging strategy can be 
used to protect the thiol group, improve the cell-permeability and 
allow controlled activation with UV. Therefore, we synthesized 
three Largazole derivatives; Largazole, Largazole thiol and 
stapled Largazole (see Supporting Information). The result of the 
parallel artificial membrane permeability assay indicated that 
stapled Largazole is a highly passively permeable compound 
(logPe –5.29 and Pe 5.3x10–6 cm/sec; Supporting Information 
Table S4). Then, the stapled Largazole was reacted with 1-thio-
β-D-glucose tetraacetate and DPAP under UV irradiation for 15 
min (Figure 2a). Full conversion of the stapled Largazole was 
observed in the HPLC trace along with the appearance of 
Largazole thiol signal (Figure 2b). Next, the growth-inhibitory 
activity was evaluated with human colon carcinoma cell lines, 
HCT-116 (Figure 2c). As expected[16], Largazole (GI50 1.433 nM) 
is more potent than the corresponding free thiol species (GI50 
185.1 nM) owing to its octanoyl side-chain which improves cell 
permeability and allows facile presentation of the free thiol within 
the cell[15]. The stapled Largazole (GI50 407.7 nM) is a much less 
potent compound because the thiol group is protected by the 
isobutylene structure, which prevents binding with the Zn2+ 
domain in cells. Before testing the decaging condition in cells, we 
investigated the toxicity of DPAP and phototoxicity of the light in 
terms of the power and the irradiation time (see Supporting 
Information, Figure S7). A set of cytocompatible conditions, 15 
min irradiation at 80 W, were chosen to conduct further 
investigations. 
 
Figure 2. The photoactivation of isobutylene-grafted Largazole thiol. a. Thiol-
ene decaging reaction of stapled Largazole with 1-thio-β-D-glucose tetraacetate. 
HPLC traces of the reaction mixture. Blue, stapled Largazole; Red, reaction 
mixture after 15 min. b. Growth inhibitory effects of Largazole, Largazole thiol 
and stapled Largazole on HCT-116 colon carcinoma cells, Largazole GI50 1.433 
nm, Largazole thiol GI50 185.1 nm, stapled Largazole GI50 407.7 nm. c. Cell 
survival under different conditions; SL, stapled Largazole, UV condition, 365 nm 
80 W, 15 min. d. HDAC activity assay of control group and UV group. Data are 
representative of three independent tests and analyzed by the two-tailed 
unpaired Student’s t-test. **, P < 0.01; ****, P < 0.0001. Error bars reflect one 
standard deviation from the mean. 
The decaging reaction of stapled was tested with HCT-116 
cells at 150 nM. McCoy's 5A culturing medium contains cysteine 
and glutathione, so no other thiol source was added to the 
medium. The cell viabilities of the three drug groups with/without 
UV irradiation were consistent with the growth-inhibitory assay 
(Figure 2d). The UV-irradiated premixed group of stapled 
Largazole and DPAP showed significantly lower cell viability than 
the corresponding non-irradiation group, the stapled Largazole 
group and the Largazole thiol group. To confirm the results, a 
fluorometric HDAC activity assay was conducted with HCT-116 
cell lysates (Figure 2e). A significant decrease of fluorescence 
was observed in the UV-irradiated premixed group relative to the 
control groups and the non-irradiation group. Both the cell viability 
and the enzyme activity results indicated that the stapled 
Largazole was successfully activated by UV light. 
In summary, we have developed a rapid and efficient thiol-ene 
based photoactivation strategy for thiol-containing drugs, caged 
with isobutylene. The radical-mediated reaction, that is triggered 
by UV light, undergoes a thiol-ene addition step to form an 
unstable radical intermediate, which is further cleaved by β-
scission to release the caged thiols. We applied this method to 
various substrates, such as N-Boc-cysteine, a cysteine-
containing peptide and the HDAC inhibitor Largazole, and 
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showed that the caged thiol-molecules, unlike their free 
counterparts, display high membrane permeability. The 
successful activation of Largazole in HCT-116 cells demonstrates 
its potential as a drug delivery and activation method for cancer 
therapy. Further investigation of the use of this strategy on 
proteins could also be extremely useful for photo-controlled 
protein activation and drug-release from antibody-drug 
conjugates. 
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An UV-initiated thiol-ene 
reaction enables 
photoactivation-mediated 
decaging of isobutylene-caged 
thiols. With this strategy, the 
activity of histone deacetylase 
inhibitor Largazole can be 
switched-off when stapled, but 
selectively switched-on when 
irradiated with non-phototoxic 
light in cancer cells. 
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